Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 5/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124249 | 0.80 | FKBP1A (0.48) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL23123407 | 0.80 | NAMPT (0.43) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL23124031 | 0.76 | EPHX2 (0.59) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL23124135 | 0.76 | NAMPT (0.48) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL24700279 | 0.73 | NAMPT (0.54) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL23123949 | 0.73 | EPHX1 (0.50) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL29789806 | 0.72 | EPHX2 (0.47) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL17117330 | 0.72 | NAMPT (0.70) | FKBP1AEPHX1EPHX2NAMPTASAH1 | |
| SCHEMBL23124014 | 0.72 | HRH3 (0.43) | EPHX1EPHX2 | |
| SCHEMBL29789773 | 0.71 | EPHX2 (0.47) | FKBP1AEPHX1EPHX2NAMPTASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |